To The Moon

Tesla shares surged over 5% after-hours despite missing Q1 expectations, posting adjusted earnings of 27 cents per share on $19.34B in revenue—well below analysts’ estimates. During the earnings call, Elon Musk revealed he’ll scale back his involvement with DOGE starting in May to refocus on Tesla.Could this signal a turning point? Is Musk’s return the boost Tesla needs? What’s your price target for TSLA?🎁Special Notes: Whoever showed up on the” What the Tigers Say” column will receive 100 Tiger Coins and an exclusive interview invitation to honor your contribution.Click titles to read the full analysis:1. @ToNi:Key Points:Technicals: A Rebound in the MakingThe daily chart tells a story of resilience. Tesla’s stock had plummeted from a

$SPDR S&P Biotech ETF ( $Spdr S&P Biotech Etf(XBI)$ )$ $Pfizer ( $Pfizer(PFE)$ )$ $S&P 500(. $S&P 500(.SPX)$ )$ $Dow Jones Industrial Average(. $Dow Jones(.DJI)$ )$As of April 18, 2025, the U.S. stock market is reeling from a volatile week, with the S&P 500 shedding 2.8% on April 17 and the Dow Jones Industrial Average dropping 1,200 points in a single session. Fears of escalating trade tensions and a hawkish Federal Reserve have sparked widespread selling. Yet, amid the chaos, biotech stocks are staging an unexpected rally, driven by breakthrough drug approvals and M&A chatter. Is this a sector to